title: Why a consensus conference on hormone replacement therapy and the cardiovascular system?
abstract: A recent randomized, placebo-control study of a combination of conjugated estrogens (0.625 mg) and medroxyprogesterone acetate (2.5 mg) known to bring considerable advantages to post-menopausal women, has concluded that the risks associated with its use outweigh the benefits. On the strength of these data the manufacturer began recommending that physicians consider alternatives to their product to treat post-menopausal symptoms. Since women take hormone replacement therapy (HRT) for compelling health reasons, it is important, not only to evaluate the new evidence, but also to translate it into terms which can be understood by women and their physicians. Although the focus of this conference is on the cardiovascular system, in order to place the present controversy in its proper perspective, it is necessary to consider also other adverse effects that frighten women, first and foremost, a possible increased risk of breast cancer. For several years it has been reported that there is an increased risk of invasive breast cancer with increased duration of HRT use, similar to what has been found for oral contraceptives. The situation is however, entirely different when addressing HRT and risk of cardiovascular diseases (CVD). Here, a large body of evidence has, for years, pointed to a protective effect. Therefore, in the case of cardiovascular risk, we must proceed very cautiously and weigh the evidence, before concluding that HRT has indeed a negative effect on cardiovascular diseases. To properly do so, we must evaluate the validity and applicability of the findings presented in the latest study, since evidence indicates that the results of the study may not be applicable to women seeking HRT at the time of menopause. We also need to try and outline an overall "risk-benefit profile" for the use of HRT and we must aim at establishing a true dialogue between all parties concerned. Finally, we must obtain information, or state the lack of it, on possible different effects among the various estrogens, routes of administration and dosages, as well as possible different actions of the various progestins, their dosages and routes of administration.
authors.affiliation: Department of Gynecological Sciences, Perinatology and Child Care, University "la Sapienza", Rome, Italy. gbenagiano@libero.it
authors.forename: G
authors.initials: G
authors.lastname: Benagiano
authors.forename: M
authors.initials: M
authors.lastname: Farris
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology*; D003245:Consensus Statements as Topic; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006266:Health Education; D006801:Humans; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic; D016387:Women's Health